Company: BWAY
Filing Date: 2025-04-22
Form Type: 20-F
Source: 0001171843-25-002347
Chunk: 121

Company: Brainsway Ltd.
Filing Date: 2025-04-22
Form: 20-F
Item: Item 5
Chunk 121
---
and approximately half (i. e., 1.5 million) are treatment resistant. Of the total OCD population, 50.6% of cases are characterized as having
severe impairment. Another 34.8% of adults with OCD had moderate impairment, and 14.6% had mild impairment. The average age of onset is
19 years old.

There is a significant overlap of patients experiencing
MDD and those experiencing OCD. Researchers found that MDD was 10 times more prevalent in OCD patients compared to the general population.
Additionally, roughly 30% of OCD patients have concurrent OCD and MDD at the time of evaluation, and 60 to 80% of OCD patients experience
a depressive episode over the course of their lifetime. Frequently, depressive symptoms follow OCD, which suggests that the depressive
symptoms occur as a response to the distress caused by OCD.

Treatment
Options for OCD

OCD is generally considered to be one of the most
difficult psychiatric diseases to treat. The wide variability in the expression of the disease and the frequent co-morbidity (simultaneous
presence) with MDD and other anxiety disorders has complicated the development of an effective, targeted treatment for OCD. The accepted
treatment for OCD is medicinal treatment, psychotherapy or a combination of both. However, up to 40% of patients do not respond to these
treatments sufficiently.

While 60-70% of patients respond or partially respond
to treatment with antidepressant medications such as SRIs or SSRIs, there is a high relapse rate of approximately 60% when medications
are stopped. The high relapse rate suggests that pharmacological treatments should be continued over an extended period of time in order
to have continued effect. In addition, when testing a new pharmacological treatment on a patient, it takes 10 to 12 weeks to determine
if the medication is bringing about clinically significant improvements in symptoms. Over half of patients experience a 25% to 35% decrease
in symptoms within 10 to 12 weeks, but symptoms rarely disappear entirely. In addition, 40-60% of OCD patients do not experience a meaningful
response to pharmacological treatment.

Deterrents to treatment include the often-severe
side effects of medications. Tricyclic antidepressant medication, generally considered to be an effective first-line OCD treatment, is
known for its particularly strong side effect profile. The medication can cause heightened risk of seizures, weight gain, sleepiness,